Eric Balkunas, senior analyst segment ETF-fund company Bloomberg, said that the best ETF fund in the current market - is PowerShares Dynamic Pharmaceuticals Portfolio (PJP), which over the past 10 years has grown by 420% - based on AMarkets.
It is interesting that a couple of years ago, leading ranking ETF-funds held assets of developing countries, however, falling prices for raw materials, weakening local currency literally knocked out of the top leaders of the past 10. PJP Fund tracks the performance of the industry with almost infinite demand from an aging population that suffers most extension of his old age and postponing certain death. In this biotechnological resource of American companies actually concentrated within the 30 companies.
Practice shows that the funds that are monitoring a small number of players, typically earn higher profits than competitors. Or, on the contrary - much less make a profit. PJP Fund could take home a great benefit from the information on M & A deals in the pharma industry. PJP stock picks for a portfolio piece, basing the choice on the fundamentals and risk factors for each asset. This personalized approach allows the fund to earn a promising small companies that sooner or later become the subject of mergers and acquisitions, in anticipation that their value increases.